Rättskällor med officiella primärkällor

Utskrivet ·

Skip to main content
Skip to the answer
ExploreWorldAIExploreWorldAI

Back to the decisions

Court of Justice of the European Union · Order

C-518/10Yeda Research and Development Company Ltd and Aventis Holdings Inc. v Comptroller General of Patents, Designs and Trade Marks

Decided
2011-11-25
ECLI
ECLI:EU:C:2011:779
CELEX
62010CO0518
Finality
Final, the decision cannot be appealed

The court's own keywords

Article 104(3), first subparagraph, of the Rules of Procedure - Medicinal products for human use - Supplementary protection certificate - Regulation (EC) No 469/2009 - Article 3 - Conditions for obtaining a certificate - Concept of a ‘product protected by a basic patent in force’ - Criteria - Marketing authorisation - Medicinal product placed on the market containing only one active ingredient whereas the patent claims a combination of active ingredients.

Interprets

    EUR-LexThe Court

    Read from EU:s publikationsbyrå, Cellar (EUR-Lex och CURIA) on 2026-08-22.

    The row repeats what the source states. It is not a summary, not a conclusion about any single case and not legal advice.

    Verifiable trust signals

    • Six fixed blocks, one source per line
    • No sentence written by a language model
    • Engine version and read date on every answer
    • No customer data, no documents, no advice
    • Model card and audit published under the EU AI Act

    Model cardAudit